The cost of genetic testing for ocular disease: Who pays?

Current Opinion in Ophthalmology

Volumn 25, Issue 5, 2014, Pages 394-399

  Capasso, Jenina E ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

gene therapy; genetic counseling; genetic testing; insurance coverage; ocular disease

Indexed keywords

EYE DISEASE; GENE THERAPY; GENETIC SCREENING; HEALTH CARE COST; HEALTH HAZARD; HEALTH INSURANCE; HUMAN; INHERITANCE; OPHTHALMOLOGIST; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EYE DISEASES, HEREDITARY; GENETIC COUNSELING; GENETIC TESTING; GENETIC THERAPY; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE;

EID: 84905988717     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000085     Document Type: Review

References (23)

1. Independence BS medical policy bulletin: genetic testing. Policy no.: 06.02.35f. Effective date 1 January 2014. http://medpolicy.ibx.com/policies/mpi. nsf/f12d23cb982d59b485257bad00552d87/85256aa800623d7a 85257c450027b880!OpenDocument.
2. Aetna SM clinical policy bulletin: genetic testing. Policy no.: 0140. Last review 31 January 2014. http://www.aetna.com/cpb/medical/data/100-199/0140. html.
3. Cigna medical coverage policies: genetic testing of heritable disorders. Policy no.: 0052. Effective date 15 September 2013. https://cignaforhcp.cigna. com/public/content/pdf/coveragePolicies/medical/mm-0052-coverageposi tioncriteria-genetic-testing.pdf in.
4. Anthem blue cross medical policy: diagnostic genetic testing of potentially affected individual (adult or child). Policy no.: GENE.00013. Current effective date 01 January 2014. http://www.anthem.com/ca/ medicalpolicies/policies/mp-pw-b082311.htm.
5. Miller CE, Krautscheid P, Baldwin EE, et al. Genetic counselor review of genetic test orders in a reference laboratory reduces unnecessary testing. Am J Med Genet A 2014; 164A:1094-1101.
6. Pradhan MA, Ng Y, Strickland A, et al. Role of genetic testing in retinoblas-toma management at a tertiary referral centre. Clin Experiment Ophthalmol 2010; 38:231-236.
7. Fischbach BV, Trout KL, Lewis J, et al. WAGR syndrome: a clinical review of 54 cases. Pediatrics 2005; 116:984-988. (Pubitemid 44542829)
8. Ganesh A, Stroh E, Manayath GJ, et al. Macular cysts in retinal dystrophy. Curr Opin Ophthalmol 2011; 22:332-339.
9. Cordovez JA, Traboulsi EI, Capasso JE, et al. Retinal dystrophy with intraretinal cystoid spaces associated with mutations in the crumbs homologue (CRB1) gene. Ophthalmic Genet 2014. [Epub ahead of print]
10. Radu RA, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci 2008; 49:3821-3829.
11. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies-disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011; 30:81-114.
12. Goetz KE, Reeves MJ, Tumminia SJ, Brooks BP. eyeGENE(R): a novel approach to combine clinical testing and researching genetic ocular disease. Curr Opin Ophthalmol 2012; 23:355-363.
13. Blain D, Goetz KE, Ayyagari R, Tumminia SJ. eyeGENE1: a vision community resource facilitating patient care and paving the path for research through molecular diagnostic testing. Clin Genet 2013; 84:190-197.
14. Hayden EC. Technology: the $1, 000 genome. Nature 2014; 507:294-295.
15. Chiang PW, Wang J, Chen Y, et al. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet 2012; 44:972-974.
16. Coppieters F, Van Schil K, Bauwens M, et al. Identity-by-descent-guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy. Genet Med 2014. [Epub ahead of print]
17. Deml B, Reis LM, Maheshwari M, et al. Whole exome analysis identifies dominant COL4A1 mutations in patients with complex ocular phenotypes involving microphthalmia. Clin Genet 2014. [Epub ahead of print]
18. Ortube MC, Strom SP, Nelson SF, et al. Whole exome sequencing detects homozygosity for ABCA4 p.Arg602Trp missense mutation in a pediatric patient with rapidly progressive retinal dystrophy. BMC Med Genet 2014; 15:11.
19. Prokudin I, Simons C, Grigg JR, et al. Exome sequencingindevelopmentaleye disease leads to identification of causal variants in GJA8, CRYGC, PAX6 and CYP1B1. Eur J Hum Genet 2013. [Epub ahead of print]
20. Yu HC, Geiger EA, Medne L, et al. An individual with blepharophimosis- ptosis-epicanthus inversus syndrome (BPES) and additional features expands the phenotype associated with mutations in KAT6B. Am J Med Genet A 2014; 164:950-957.
21. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral && subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013; 120:1283-1291.
22. Koilkonda RD, Yu H, Chou TH, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthal-mol 2014; 132:409-420.
23. Seo S, Mullins RF, Dumitrescu AV, et al. Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1. Invest Ophthalmol Vis Sci 2013; 54:6118-6132.